Asta Medica, Aktiengesellschaft

Asta Pharma Aktiengesellschaft

Zentaris Gmbh

Zentaris Ag

Degussa Aktiengesellschaft

Degussa Gmbh

Aeterna Zentaris Gmbh

Zentaris Ivf Gmbh

Dieter Sauerbier

Jurgen Engel

Burkhard Wichert

Eckhard Milsmann

Thomas Reissmann

Elisabeth Wolf-Heuss

Otto Isaac

Jürgen Engel

Wolfgang Deger

Giancarlo Camuglia

Klaus Molge

Gerhard Scheffler

Peter Hilgard

J&uuml;rgen Engel

Thomas Klenner

Werner Sarlikiotis

Juergen Engel

Jurgen Rawert

Wolfgang P Brade

Werner Weigert

Otto Issac

Uwe-Peter Dammann

Helmut Orth

Gudrun Sauerbier, Legal Representative

A novel lyophilizate and method of preparation as well as the use of the lyophilizate to treat female infertility and for gonad protection. Cetrorelix is dissolved in acetic acid 30% v/v, the solution is transferred to water and freeze dried.

Oligopeptide lyophilisate, their preparation and use

A lyophilizate, method of preparation, and use of the lyophilizate for gonad protection is described. The lyophilizate comprises cetrorelix dissolved in 30% (v/v) acetic acid, transferred to water, and freeze-dried.

Preparation and use of oligopeptide lyophilisate for gonad protection

The present invention relates to new solid pharmaceutical compositions containing hexadecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis, a process for the manufacture of said pharmaceutical composition, a dosage scheme for oral administration of said pharmaceutical composition in the treatment of leishmaniasis, and finally a combination comprising said solid pharmaceutical composition, antiemeticum, and/or an antidiarrhoeal.

Solid pharmaceutical compositions containing hexedecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis

Injectable mesna solutions having a pH value higher than 7.5. The solutions have increased storage stability.

Container for injectable mesna solutions

The invention relates to improved ifosfamide preparations which are distinguished in that as primary auxiliary a polysaccharide, in general a glycan, preferably dextran, starches or cellulose, in particular dextrans having an MW of 20,000 to 85,000, modified starches such as hydroxyethyl starch and chemically modified celluloses such as hydroxyethylcellulose and sodium carboxymethylcellulose, a glycol ether, preferably polyethylene glycol, in particular polyethylene glycols having a molecular weight of 600 to 6000 or an amino acid, preferably alanine, leucine or glutamic acid, is added to them. The improved ifosfamide preparation can also contain as an auxiliary a pharmaceutically customary buffer, for example acetate, citrate or tris buffer, preferably phosphate buffer. In addition, improved ifosfamide preparations are obtained by addition of NaHCO.sub.3. The ifosfamide preparations according to the invention can comprise one or a combination of several auxiliaries. Mesna can be added to the formulation as a uroprotector.

Ifosfamide lyophilizate preparations

Injectable mesna solutions

Solutions of alkylphosphocholines in glycerol alkyl ethers having enhanced storage stability containing a buffer which maintains the pH value to a range between 4 and 6.

Stabilized hexadecylphosphocholine solutions in glycerol alkyl ethers

A granulate containing mesna is made by granulating mesna in the presence of an alcohol, acetone or a mixture of one of these with water. The granulate may be converted to tablets, along with other agents. The tablets contain:

Tablet containing mesna as active substance and method of making same

Tablets and granulates containing mesna as active substance

A granulate containing mesna is made by granulating mesna in the presence of an alcohol, acetone or a mixture of one of these with water. The granulate may be converted to tablets, along with other agents. The tablets contain

An embonic acid salt of azelastine is disclosed which does not possess the bitter taste of azelastine, and which therefore is suitable for orally administered formulations.

Azelastine embonate and compositions which contain it

Ifosfamide lyophilizate consisting substantially of ifosfamide and 0.1 to 17 parts by weight of a hexitol.

Ifosfamide lyophilisate and process for its preparation

Growing community of inventors

Werther, Germany

Dieter Sauerbier